Tengion Inc. Provides Business Update and Reports Second Quarter 2013 Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WINSTON-SALEM, N.C., Aug. 14, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the second quarter ended June 30, 2013.
"We made strong progress advancing our Neo-Kidney Augment into the clinic this quarter and will continue to focus on this program as well as completing enrollment in our Neo-Urinary Conduit trial. During the quarter, we received a $15.0 million strategic investment from Celgene and completed a $18.6 million financing with other experienced investors to fund our efforts to accomplish these goals," commented John L. Miclot, President and Chief Executive Officer of Tengion.
Hey, check out all the research scientist jobs. Post your resume today!
WINSTON-SALEM, N.C., Aug. 14, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the second quarter ended June 30, 2013.
"We made strong progress advancing our Neo-Kidney Augment into the clinic this quarter and will continue to focus on this program as well as completing enrollment in our Neo-Urinary Conduit trial. During the quarter, we received a $15.0 million strategic investment from Celgene and completed a $18.6 million financing with other experienced investors to fund our efforts to accomplish these goals," commented John L. Miclot, President and Chief Executive Officer of Tengion.
Hey, check out all the research scientist jobs. Post your resume today!